Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MC4R | P32245 | 11/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771297 | 0.80 | NPSR1 (0.46) | NPSR1ALDH1A1MEN1KMT2AMCOLN3 | |
| SCHEMBL4776952 | 0.79 | LMNA (0.46) | NPSR1ALDH1A1MC4RMEN1KMT2A | |
| SCHEMBL4779189 | 0.78 | NPSR1 (0.43) | NPSR1ALDH1A1MEN1KMT2AMCOLN3 | |
| SCHEMBL4776587 | 0.77 | KDM4E (0.45) | NPSR1ALDH1A1MEN1KMT2AMCOLN3 | |
| SCHEMBL4773595 | 0.75 | ALDH1A1 (0.43) | NPSR1ALDH1A1MEN1KMT2AMCOLN3 | |
| SCHEMBL4770304 | 0.73 | NPSR1 (0.39) | NPSR1ALDH1A1MEN1KMT2AMCOLN3 | |
| SCHEMBL23549955 | 0.71 | USP2 (0.55) | NPSR1ALDH1A1MC4RMEN1KMT2A | |
| SCHEMBL19403828 | 0.71 | USP2 (0.55) | NPSR1ALDH1A1MC4RMEN1KMT2A | |
| SCHEMBL4778512 | 0.71 | MC4R (0.58) | ALDH1A1MC4RMEN1KMT2AUSP2 | |
| SCHEMBL19403735 | 0.70 | NPSR1 (0.45) | NPSR1ALDH1A1MC4RMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |